(Reuters) – Regeneron Pharmaceuticals Inc beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for eczema treatment Dupixent.
The company reported adjusted profit of $10.24 per share for the second quarter, topping analysts’ average estimates of $9.84, according to Refinitiv data.
Advertisement
(Reporting by Khushi Mandowara in Bengaluru)
By: OAN
Advertisement
(function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13348268193035366,size:[0, 0],id:”ld-4546-3812″});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src=”//cdn2.lockerdomecdn.com/_js/ajs.js”;j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,”script”,”ld-ajs”);